Shire to eke out ‘precious’ Vyvanse as European ADHD launch nears
This article was originally published in Scrip
Executive Summary
Shire is not expecting "huge sales" of Vyvanse (lisdexamfetamine dimesylate) in Europe this year, following its approval under the decentralized procedure at the end of December (scripintelligence.com, 20 December 2012), says CEO Angus Russell (aka Bilbo Baggins, since he is due to leave Shire soon; scripintelligence.com 25 October 2013). The new ADHD drug will be launched in the UK first, probably in April, and then Germany, he added, speaking at the JP Morgan global healthcare conference on 8 January.